Wallace v. Pharma Medica Research, Inc.

District Court, E.D. Missouri·Decided February 11, 2021·No. 4:18-cv-01859·Unknown

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MISSOURI EASTERN DIVISION

IAN WALLACE, ) ) Plaintiff, ) ) v. ) Case no. 4:18cv01859 PLC ) PHARMA MEDICA RESEARCH, INC., ) et al., ) ) Defendants. )

MEMORANDUM AND ORDER This matter is before the Court on Defendant Tris Pharma’s Inc.’s motion for summary judgment. [ECF No. 114] Plaintiff Ian Wallace opposes the motion. [ECF No. 127]] The parties submitted the same materials in support of their summary judgment positions.1 For the following reasons, the Court grants Tris Pharma’s motion.2 I. Background This case arises from Plaintiff’s infection with hepatitis C. Plaintiff claims that the infection was caused by blood draws he underwent while participating in two clinical studies at Pharma Medical Research, Inc.’s (PMR) medical research facility. Tris sponsored one of those studies.

1 Specifically, both Plaintiff and Tris submitted the: transcript of the November 7, 2019 deposition of Shabaz Kahn, M.D.; transcript of the July 30, 2019 deposition of Heather Jordan, M.D.; and contract between Tris and PMR, titled “Master Service Agreement.” Plaintiff also submitted Tris’s answers to interrogatories, a December 10, 2020 email from Plaintiff’s counsel to Tris’s counsel, and Protocol 2015-3952, which pertains to the Tris study in which Plaintiff participated that is at issue in this case. 2 The parties consented to the jurisdiction of the undersigned pursuant to 28 U.S.C. § 636(c). [ECF No. 14] The undisputed record reveals the following. In 2016, Plaintiff voluntarily participated in a study at PMR’s St. Charles facility that was sponsored by Tris. [ECF No. 116 at ¶ 7] During the study, participants were subject to multiple blood draws. PMR “worked on a contract basis with pharmaceutical companies to test and gather data for testing pharmaceuticals that the pharmaceutical companies wanted to market.” [ECF No. 116

at ¶ 13] Dr. Shabaz Khan was PMR’s vice president of clinical operations. [Id. at ¶ 16] Dr. Heather Jordan was a principal investigator at PMR’s St. Charles facility from March 2015 to May 2019. [Id. at ¶ 23] Dr. Jordan’s duties included ensuring each study assigned to her, including the ones in which Plaintiff participated, was conducted in accordance with the study’s protocol. [Id. at ¶ 24] PMR conducted its studies pursuant to protocols, which “governed everything ranging from what medication to administer to he time a participant’s blood was to be drawn and tested.” [Id. at ¶¶ 14, 25] PMR’s scientific affairs and protocol-writing teams drafted protocols in accordance with Food and Drug Administration (FDA) guidelines and in consultation with the

study sponsor. [ECF Nos. 116 at ¶¶ 15; 116-3 at 5] According to Dr. Khan’s deposition testimony, a study protocol must comply with FDA guidelines, but “any other studies [sic] specific design and all, the sponsor will have an input. It’s their study.” [ECF No. 116-3 at 6 ] Dr. Khan affirmed that the use of catheters rather than needles for blood draws would require the approval of both PMR’s scientific affairs department and the study sponsor. [Id. at 8] Tris retained PMR to conduct clinical studies of its pharmaceutical products, and they entered into a Master Service Agreement (“Agreement”). [ECF Nos. 116 at ¶ 6, 116-2] The Agreement set forth the parties’ contractual rights and obligations. [ECF No. 116-2] Among other things, the Agreement required PMR to: provide written status reports as reasonably requested by Tris; “perform the Services under the general direction of Tris’ designated representative”; “assign to Tris all right, title, and interest” in “all data and Intellectual Property Rights” that PMR’s personnel or subcontractors created, developed, or conceived; “maintain in strict confidence” all confidential information received from Tris or “of which [PMR] bec[ame] aware in connection with this Agreement”; permit Tris’s representatives to examine or audit PMR’s facilities, systems,

equipment, and records; and maintain adequate insurance. [ECF No. 116-2 at §§ 2.2, 2.9, 8.1, 9.1, 10.5, 17.1] The Agreement allowed PMR to “use subcontractors to perform part of the Services,” but only if Tris approved and the subcontractor agreed to the terms contained in the Agreement. [Id. at § 2.6] Tris also had the right to approve the personnel that PMR assigned to studies of Tris’s medications. [Id. at § 2.11] Under a section entitled “Independent Contractor Status,” the Agreement provided: It is understood and agreed that [PMR] is an independent contractor and will not have any rights to any of Tris benefits, nor for any purposes be deemed or intended to be an employee of Tris. [PMR] agrees to make any payments or withholding required by the Internal Revenue Code of 1986, as amended, the regulations promulgated thereunder, social security and any related statute or regulations.

[Id. at § 11.1] The Agreement further stated: “[PMR] is not an agent of Tris and Tris is not an agent of [PMR] and neither party is authorized to bind the other party with respect to any third party.” [Id. at § 11.2] Plaintiff filed a second amended complaint asserting claims of negligence (Count II) and res ispsa loquitor (Count V) against Tris. [ECF No. 76] Plaintiff premised these claims on an agency theory. [Id.] Specifically, Plaintiff alleged that: (1) Tris “sponsored as master and PMR as agent a certain study at PMR’s St. Charles, Missouri facility” in which Plaintiff participated; (2) Tris contracted with PMR “to test on humans a certain medications designed, manufactured, supplied, and created” by Tris; (3) Tris “controlled the actions of [PMR] or had the right to control the actions of [PMR] in said study”; and (4) PMR was “acting as the agent for [Tris] in the scope of its employment by [Tris] for the aforesaid study.” [ECF No. 76 at 1, 4, 8] According to Plaintiff, Tris is therefore “responsible for [PMR’s] actions during the study.” [Id. at 4, 8] Tris moves for summary judgment on the ground that PMR was not Tris’s agent and, therefore, “any claims of negligence cannot be imputed to Tris.” [ECF No. 114 at ¶ 4] In response,

Plaintiff asserts that summary judgment is inappropriate procedurally and the evidence establishes the existence of an agency relationship between Tris and PMR. [ECF No. 127] II. Legal Standard Summary judgment is proper “if the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a); Hill v. Walker, 737 F.3d 1209, 1216 (8th Cir. 2013). The movant “bears the initial responsibility of informing the district court of the basis for its motion” and must identify “those portions of [the record]...which it believes demonstrate the absence of a genuine issue of material fact.” Celotex Corp. v. Catrett, 477 U.S. 317, 323 (1986). Once the moving party makes this showing, “the

nonmovant must respond by submitting evidentiary materials that set out specific facts showing that there is a genuine issue for trial.” Torgerson v. City of Rochester, 643 F.3d 1031, 1042 (8th Cir. 2011) (en banc) (quotation omitted). “On a motion for summary judgment, ‘facts must be viewed in the light most favorable to the nonmoving party only if there is a genuine dispute as to those facts.’” Ricci v. DeStefano, 557 U.S. 557, 586 (2009) (quoting Scott v.

Free access — add to your briefcase to read the full text and ask questions with AI

Wallace v. Pharma Medica Research, Inc., (E.D. Mo. 2021).

Wallace v. Pharma Medica Research, Inc. (Wallace v. Pharma Medica Research, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Scott v. Harris
550 U.S. 372 (Supreme Court, 2007)
Ricci v. DeStefano
557 U.S. 557 (Supreme Court, 2009)
FREVERT v. Ford Motor Co.
614 F.3d 466 (Eighth Circuit, 2010)
Weitz Co. v. MH WASHINGTON
631 F.3d 510 (Eighth Circuit, 2011)
Torgerson v. City of Rochester
643 F.3d 1031 (Eighth Circuit, 2011)
Vincent Goka v. Paul Bobbitt, Officer, Acting Sergeant
862 F.2d 646 (Seventh Circuit, 1988)
Stricker v. Union Planters Bank
436 F.3d 875 (Eighth Circuit, 2006)
Reeves v. Sanderson Plumbing Products, Inc.
530 U.S. 133 (Supreme Court, 2000)
Goede v. Aerojet General Corp.
143 S.W.3d 14 (Missouri Court of Appeals, 2004)
State Ex Rel. Ford Motor Co. v. Bacon
63 S.W.3d 641 (Supreme Court of Missouri, 2002)
Ritter v. BJC Barnes Jewish Christian Health Systems
987 S.W.2d 377 (Missouri Court of Appeals, 1999)
West v. Sharp Bonding Agency, Inc.
327 S.W.3d 7 (Missouri Court of Appeals, 2010)
Gasperini v. Center for Humanities, Inc.
518 U.S. 415 (Supreme Court, 1996)
Sanders v. Ahmed
364 S.W.3d 195 (Supreme Court of Missouri, 2012)
Yulanda Hill v. Carolyn Walker
737 F.3d 1209 (Eighth Circuit, 2013)
Christine Winter v. Novartis Pharmaceuticals Corp.
739 F.3d 405 (Eighth Circuit, 2014)